{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:41:49Z","timestamp":1715982109975},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T00:00:00Z","timestamp":1245974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,1]]},"abstract":"<jats:title>Learning Objectives<\/jats:title>\n               <jats:p>Evaluate recent data regarding outcomes of autologous and allogeneic stem cell transplant for follicular lymphoma. Apply patient and disease characteristics to predict favorable post-transplant outcomes for patients with follicular lymphoma. Enumerate the indications for referral of patients with follicular lymphoma to a transplant center. Compare the advantages and disadvantages of allogeneic versus autologous stem cell transplant for follicular lymphoma.<\/jats:p>\n               <jats:p>This article is available for continuing medical education credit at CME.TheOncologist.com.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0045","type":"journal-article","created":{"date-parts":[[2009,6,27]],"date-time":"2009-06-27T02:01:51Z","timestamp":1246068111000},"page":"726-738","source":"Crossref","is-referenced-by-count":6,"title":["Role of Hematopoietic Stem Cell Transplant in the Management of Follicular Lymphoma"],"prefix":"10.1093","volume":"14","author":[{"given":"Matthew","family":"Foster","sequence":"first","affiliation":[{"name":"University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don A.","family":"Gabriel","sequence":"additional","affiliation":[{"name":"University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Shea","sequence":"additional","affiliation":[{"name":"University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,6,26]]},"reference":[{"key":"2021122207245224500_R1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122207245224500_R2","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"2021122207245224500_R3","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R4","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R5","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.V74.7.2579.2579","article-title":"Autologous bone marrow transplantation in follicular non-Hodgkin\u2019s lymphoma before and after histologic transformation","volume":"74","author":"Schouten","year":"1989","journal-title":"Blood"},{"key":"2021122207245224500_R6","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"2021122207245224500_R7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.V112.11.975.975","article-title":"Salvage therapy with allogeneic stem cell transplantation results in better outcome for patients with relapsed\/refractory follicular lymphoma compared to those with transformed non-Hodgkin lymphoma: A population-based comparative study[abstract 975]","volume":"112","author":"Ramadan","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"2021122207245224500_R9","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R10","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"2021122207245224500_R11","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"2021122207245224500_R12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207245224500_R13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: A survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"key":"2021122207245224500_R14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","article-title":"Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission","volume":"13","author":"Brown","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207245224500_R15","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","article-title":"Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R16","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R17","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","article-title":"New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors","volume":"21","author":"Baker","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","article-title":"Solid cancers after bone marrow transplantation","volume":"19","author":"Bhatia","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbmt.2004.11.017","article-title":"Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma","volume":"11","author":"Laudi","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207245224500_R20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin\u2019s lymphoma: A 16-year follow-up study","volume":"93","author":"Sacchi","year":"2008","journal-title":"Haematologica"},{"key":"2021122207245224500_R21","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"2021122207245224500_R22","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: An EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"2021122207245224500_R23","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.leu.2401488","article-title":"Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for long-term clinical and molecular remissions","volume":"13","author":"Tarella","year":"1999","journal-title":"Leukemia"},{"key":"2021122207245224500_R24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/blood.V112.11.1140.1140","article-title":"Addition of rituximab to mobilization and conditioning overcomes the predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) score in patients with relapsed FL undergoing autologous stem cell transplantation (AUTO)[abstract 1140]","volume":"112","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/annonc\/mdn044","article-title":"Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma","volume":"19","author":"Arcaini","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207245224500_R26","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2007.14.4204","article-title":"Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey","volume":"26","author":"Tarella","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2005.05827.x","article-title":"Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: In vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device","volume":"132","author":"van Heeckeren","year":"2006","journal-title":"Br J Haematol"},{"key":"2021122207245224500_R28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0301-472X(02)00828-7","article-title":"CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: High purging efficiency but increased risk of severe infections","volume":"30","author":"Alt\u00e8s","year":"2002","journal-title":"Exp Hematol"},{"key":"2021122207245224500_R29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/bbmt.2002.v8.pm12064366","article-title":"Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation","volume":"8","author":"Crippa","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207245224500_R30","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: Results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R31","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"2021122207245224500_R32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"2021122207245224500_R33","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"2021122207245224500_R34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bmt.1704124","article-title":"Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma","volume":"32","author":"Howe","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"2021122207245224500_R35","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R36","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"2021122207245224500_R37","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/JCO.2004.05.035","article-title":"Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin\u2019s lymphoma","volume":"22","author":"Hoerr","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R38","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bmt.1705849","article-title":"Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma","volume":"40","author":"Kang","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021122207245224500_R39","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V112.11.772.772","article-title":"Autologous stem cell transplantation after myeloablative therapy in first remission may be beneficial in patients with advanced stage follicular lymphoma after front-line therapy with R-CHOP. An analysis of two consecutive studies of the German Low Grade Lymphoma Study Group (GLSG)[abstract 772]","volume":"112","author":"Hiddemann","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood.V112.11.2599.2599","article-title":"Rituximab in combination with CHOP in patients with follicular lymphoma: Analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 months[abstract 2599]","volume":"112","author":"Buske","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R42","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122207245224500_R44","first-page":"783","article-title":"Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"2021122207245224500_R45","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1182\/blood.V90.10.4201","article-title":"Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Verdonck","year":"1997","journal-title":"Blood"},{"key":"2021122207245224500_R46","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","article-title":"Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation","volume":"32","author":"Mandigers","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"2021122207245224500_R47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect","volume":"19","author":"van Besien","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2021122207245224500_R48","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","article-title":"Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin\u2019s lymphoma: A comparison with allogeneic and autologous transplantation\u2014the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation","volume":"21","author":"Bierman","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R49","doi-asserted-by":"crossref","first-page":"382s","DOI":"10.1200\/jco.2008.26.15_suppl.7041","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkin\u2019s lymphoma (FL) beyond first complete response or first partial response[abstract 7041]","volume":"26","author":"Laport","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R50","first-page":"175","article-title":"Reduced-intensity allogeneic stem cell transplantation for follicular lymphoma results in an improved progression free survival when compared to autologous stem cell transplantation. An analysis from the Lymphoma Working Party of the EBMT[abstract 458]","volume":"112","author":"Robinson","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","article-title":"Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma","volume":"141","author":"Ingram","year":"2008","journal-title":"Br J Haematol"},{"key":"2021122207245224500_R52","doi-asserted-by":"crossref","first-page":"381s","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Impact of the intensity of conditioning regimen in 144 patients with follicular lymphoma (FL) receiving a matched unrelated donor stem cell transplant (MUD-SCT): An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (LWP-EBMT)[abstract 7036]","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R53","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","article-title":"Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma","volume":"25","author":"Nagler","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2021122207245224500_R54","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"2021122207245224500_R55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bmt.1705027","article-title":"Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: A retrospective survey of 112 adult patients in Japan","volume":"36","author":"Kusumi","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2021122207245224500_R56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R57","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R58","doi-asserted-by":"crossref","first-page":"150a","DOI":"10.1182\/blood.V110.11.486.486","article-title":"Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901[abstract 486]","volume":"110","author":"Shea","year":"2007","journal-title":"Blood"},{"key":"2021122207245224500_R59","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"2021122207245224500_R60","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin\u2019s lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207245224500_R61","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2008.02.014","article-title":"Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation","volume":"14","author":"Tomblyn","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207245224500_R62","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R63","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2021122207245224500_R64","doi-asserted-by":"crossref","volume-title":"Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies\u2013A Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation study","author":"Rodrigues","DOI":"10.1200\/JCO.2007.15.8865"},{"key":"2021122207245224500_R65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.bmt.1705467","article-title":"Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies","volume":"38","author":"Lekakis","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2021122207245224500_R66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R67","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"2021122207245224500_R68","doi-asserted-by":"crossref","first-page":"102a","DOI":"10.1182\/blood.V108.11.327.327","article-title":"90Y-ibritumomab tiuxetan (Zevalin) in combination with high-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) may improve survival in patients with poor-risk follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL): Results of a retrospective comparative analysis[abstract 327]","volume":"108","author":"Nademanee","year":"2006","journal-title":"Blood"},{"key":"2021122207245224500_R69","first-page":"684","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced indolent non-Hodgkin lymphoma: Interim analysis of a phase II study[abstract 1959]","volume":"112","author":"Bethge","year":"2008","journal-title":"Blood"},{"key":"2021122207245224500_R70","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults &gt; or = 60 years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207245224500_R71","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"2021122207245224500_R72","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"2021122207245224500_R73","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/7\/726\/41841425\/oncolo_14_7_726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/7\/726\/41841425\/oncolo_14_7_726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:51:18Z","timestamp":1640163078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/7\/726\/6397967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,26]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,6,26]]},"published-print":{"date-parts":[[2009,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0045","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,7,1]]},"published":{"date-parts":[[2009,6,26]]}}}